Reviewing Redhill Biopharma (NASDAQ:RDHL) and Its Competitors

Redhill Biopharma (NASDAQ: RDHL) is one of 306 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Redhill Biopharma to similar companies based on the strength of its dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Redhill Biopharma and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Redhill Biopharma 0 0 4 0 3.00
Redhill Biopharma Competitors 790 3131 11432 227 2.71

Redhill Biopharma presently has a consensus target price of $26.75, indicating a potential upside of 400.00%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.87%. Given Redhill Biopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Redhill Biopharma is more favorable than its rivals.

Risk & Volatility

Redhill Biopharma has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Redhill Biopharma’s rivals have a beta of 5.91, indicating that their average share price is 491% more volatile than the S&P 500.

Earnings and Valuation

This table compares Redhill Biopharma and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Redhill Biopharma $100,000.00 -$29.37 million -2.14
Redhill Biopharma Competitors $288.09 million $35.08 million 150.95

Redhill Biopharma’s rivals have higher revenue and earnings than Redhill Biopharma. Redhill Biopharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares Redhill Biopharma and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Redhill Biopharma N/A -70.00% -57.98%
Redhill Biopharma Competitors -5,310.02% -487.12% -42.47%

Institutional and Insider Ownership

11.0% of Redhill Biopharma shares are held by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


Redhill Biopharma rivals beat Redhill Biopharma on 7 of the 12 factors compared.

About Redhill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with's FREE daily email newsletter.

Leave a Reply